B-cell malignancies
Drug research and approvals for B-cell malignancies: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 831 studies of B-cell malignancies are recruiting on ClinicalTrials.gov, and Health Canada has authorized 12 drug trials for it since 2013.
- Recruiting worldwide: 831
- Trials authorized in Canada: 12
- FDA orphan approvals: 0
- EU medicines: 0
Newest posted first, of 831 recruiting on ClinicalTrials.gov ↗
- First in Human Study of a Dual Targeting CD20 and CD19 CAR T Cell Treatment for Patients With B Cell Blood Cancers That…NCT07948733 · Phase 1 · Cellogen Therapeutics Pvt. Ltd. · starts Oct 26, 2026
- Simulation-Free Single-Fraction Radiation Therapy for Indolent LymphomaNCT07945470 · Not applicable · University Health Network, Toronto · starts Oct 9, 2026
- A Personalised Anti-fatigue Program for Community-dwelling People With Chronic Lymphocytic LeukaemiaNCT07940920 · Not applicable · University of Surrey · starts Dec 1, 2026
- ^68Ga-grazytracer PET for In Vivo Visualization of Immune Cell Effector FunctionsNCT07935174 · Not applicable · Peking University Third Hospital · starts Jun 1, 2026
- Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment…NCT07934537 · Phase 4 · Shanghai Tongji Hospital, Tongji University School of Medicine · starts Oct 30, 2025
- Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute…NCT07936266 · Phase 1 · Sunil G. Iyer · starts Mar 31, 2027
- CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaNCT07927816 · Phase 1 · Liping Dou · starts Sep 1, 2026
- High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting…NCT07926217 · Phase 2 · Sung-Han Kim · starts Nov 2, 2026
- GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic LeukemiaNCT07910708 · Phase 1 · Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital · starts Aug 4, 2026
The 10 newest of 12; search them all in Canada trials
| Sep 4, 2026 | Baf_frontier-1, a first-in-human, phase 1 trial to assess safety, tolerability, and preliminary efficacy of LY4152199, a B-cell activation factor receptor…LY4152199 | Eli Lilly | Pending |
| Jul 18, 2024 | A phase I trial of CLIC-2201 for the treatment of relapsed/refractory b cell malignanciesCLIC-2201 / Fludarabine phosphate / Cyclophosphamide | BC Cancer, Part of The Provincial Health Services Authority | Ongoing |
| Jun 28, 2024 | A modular phase I/II open-label dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of AZD5492, a…AZD5492 | AstraZeneca Pharmaceuticals | Ongoing |
| Sep 29, 2023 | First-in-human study to evaluate the safety, pharmacokinetics, and preliminary efficacy of the btk degrader, ABBV-101, in participants with B-cell malignanciesABBV-101 | AbbVie | Ongoing |
| Mar 22, 2023 | A phase 1/2,open-label,multicenter, dose escalation and cohort expansion study of the safety and efficacy of ANTI-CD19 allogeneic CRISPR-CAS9-engineered t…CTX112 | CRISPR Therapeutics | Pending |
| Dec 16, 2022 | A phase 2, open-label, multicentre, basket study evaluating the safety and efficacy of brexucabtagene autoleucel in adults with rare B-cell malignancies…Tecartus | Kite, A Gilead Company | Pending |
| Nov 2, 2022 | A first-in-human multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-319 in B-cell…ABBV-319 | AbbVie | Ongoing |
| Jul 28, 2022 | A phase 1/2, open-label, dose-escalation and -expansion study of the bruton tyrosine kinase targeted protein degrader BGB-16673 in patients with B-cell…Tacabrutideg (BGB-16673) | BeOne Medicines | Ongoing |
| May 20, 2022 | A multicenter, open-label, phase 2 basket study to evaluate the safety and efficacy of mk¿2140 as a monotherapy and in combination in participants with…Zilovertamab vedotin (MK-2140) / Nemtabrutinib (MK-1026) | Merck & Co. (MSD) | Ongoing |
| Feb 15, 2022 | A single arm, open-label, phase 1b trial of epcoritamab in pediatric patients with relapsed/ refractory aggressive matur B-cell neoplasmsEpcoritamab (ABBV-GMMAB-3013) / Tocilizumab | AbbVie | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA